CryoPort, Inc. (NASDAQ:CYRX) Receives $12.00 Consensus Target Price from Analysts

Key Points

• CryoPort, Inc. has received an average rating of "Buy" from ten analysts, with a consensus price target set at $12.00.
• Insider trading activity includes CEO Jerrell Shelton selling over 151,000 shares for approximately $1 million, indicating a 14.22% decrease in his position.
• Institutional investors now hold about 92.90% of CryoPort's shares, with notable increases in holdings from several hedge funds in the past quarter.

Shares of CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) have been assigned a consensus rating of "Buy" from the ten analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $12.00.

A number of equities research analysts have recently commented on CYRX shares. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price on the stock in a research note on Wednesday, August 6th. Leerink Partnrs upgraded CryoPort from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 6th. KeyCorp upgraded CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 target price on the stock in a research note on Wednesday, August 6th. BTIG Research lowered their target price on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, July 7th. Finally, Stephens assumed coverage on CryoPort in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 target price on the stock.

Insider Transactions at CryoPort

In related news, Director Ramkumar Mandalam sold 40,728 shares of the business's stock in a transaction dated Tuesday, July 22nd. The stock was sold at an average price of $7.24, for a total value of $294,870.72. Following the sale, the director directly owned 92,328 shares in the company, valued at approximately $668,454.72. The trade was a 30.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert J. Hariri sold 5,000 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $8.60, for a total value of $43,000.00. Following the completion of the sale, the director owned 26,275 shares in the company, valued at $225,965. This represents a 15.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 435,125 shares of company stock valued at $2,992,628. 10.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CryoPort

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC raised its stake in CryoPort by 11.0% in the 4th quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock valued at $32,208,000 after acquiring an additional 409,353 shares during the period. Thematics Asset Management boosted its position in shares of CryoPort by 12.8% in the second quarter. Thematics Asset Management now owns 1,914,885 shares of the company's stock valued at $14,285,000 after acquiring an additional 216,937 shares during the period. Deutsche Bank AG boosted its position in shares of CryoPort by 0.9% in the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company's stock valued at $10,870,000 after acquiring an additional 12,864 shares during the period. Geode Capital Management LLC boosted its position in shares of CryoPort by 7.8% in the second quarter. Geode Capital Management LLC now owns 1,203,061 shares of the company's stock valued at $8,977,000 after acquiring an additional 87,418 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of CryoPort by 7.3% in the second quarter. Assenagon Asset Management S.A. now owns 1,090,511 shares of the company's stock valued at $8,135,000 after acquiring an additional 73,949 shares during the period. 92.90% of the stock is currently owned by institutional investors.

CryoPort Stock Up 0.2%

NASDAQ:CYRX traded up $0.02 during trading hours on Thursday, hitting $10.06. 108,608 shares of the company traded hands, compared to its average volume of 536,964. The company has a market cap of $503.72 million, a PE ratio of 7.56 and a beta of 1.62. CryoPort has a one year low of $4.58 and a one year high of $10.46. The company has a quick ratio of 15.47, a current ratio of 16.24 and a debt-to-equity ratio of 0.39. The firm's 50-day simple moving average is $8.08 and its 200-day simple moving average is $6.82.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). The business had revenue of $45.45 million for the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%. CryoPort has set its FY 2025 guidance at EPS. Equities analysts predict that CryoPort will post -0.99 earnings per share for the current year.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.